Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

First Albany Downgrades Genentech

First Albany downgrades Genentech (DNA) to neutral from buy.

Analyst David Webber says fourth-quarter results disappointing and the company's 2005 guidance implies lower-than-expected earnings per share this year. He notes the company posted 21 cents fourth-quarter earnings per share, vs. his 19 cents and consensus 22 cents estimates.

He says fourth-quarter sales of all major products were slightly below expectations, and total operating revenues also were weaker than expected. Meanwhile, he notes the company sees 2005 non-GAAP earnings per share growth of 25%-plus, implying $1.04 at the low end.

Based on 2005 guidance and fourth-quarter results, Webber cuts his $1.10 2005 earnings per share estimate to $1.02, $1.59 2006 earnings per share estimate to $1.40, and $2.07 2007 earnings per share to $1.90. He lowers his $63 price target to $51.

blog comments powered by Disqus